(Q38014920)

27 August 2017

title

Using antibodies to target cancer therapeutics (English)

1 reference

27 August 2017

David M Goldenberg

1

1 reference

27 August 2017

Robert M Sharkey

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1173-1190

1 reference

Therapeutic additions and possible deletions in oncology in 2011.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Generation of recombinant antibodies and means for increasing their affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Introduction to current and future protein therapeutics: a protein engineering perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Engineering the variable region of therapeutic IgG antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Recombinant antibodies: engineering and production in yeast and bacterial hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Optimizing therapeutic antibody function: progress with Fc domain engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Engineered protein scaffolds as next-generation antibody therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Overview of mimotopes and related strategies in tumor vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Design of an optimized scaffold for affibody molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A chemical study of rabbit antiovalbumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Studies on structural units of the gamma-globulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody-based therapy for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Strategies to extend plasma half-lives of recombinant antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody vectors for imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Engineered Antibodies as Pharmacological Tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Single-domain antibodies as building blocks for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The zone of localization of antibodies; the specific localization of antibodies to rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Advances in radioimmunotherapy in the age of molecular engineering and pretargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Scaling rules for diffusive drug delivery in tumor and normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeting: the ADEPT story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeted enzyme prodrug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CD74 is expressed by multiple myeloma and is a promising target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CD74: a new candidate target for the immunotherapy of B-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Nectin-4 is a new histological and serological tumor associated marker for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeted toxins in brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Therapeutic potential of anticancer immunotoxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Targeted drug delivery using immunoconjugates: principles and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Cell-targeting fusion constructs containing recombinant gelonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Generation of bispecific and tandem diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693472

10.1517/14712598.2012.693472

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference